drugset / Trial / NCT03873025
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 1/2
Withdrawn
University College, London
Celleron Therapeutics Ltd. · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
Trial Subjects (patients), will receive single infusions of pembrolizumab in combination with CXD101 every 3 weeks for two years or until disease progression or unacceptable toxicity develops.
Timeline
- Start
- 2019-10
- Primary completion
- 2024-04
- Completion
- 2025-04
Outcome
Outcome not reported
Stopped (Enrollment): “There are insufficent funds to open the trial and start recruiting patients due to the impact of the COVID-19 pandemic.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Zabadinostat | Small molecule | 10 mg | Oral |
| Subject | Zabadinostat | Small molecule | 20 mg | Oral |